Cycling to work linked to 21% lower risk of death from any cause

Sedentary behaviour is one of the larger risks for early death, and the commute is one of the few slots in a working day where movement can be built in without extra time. Walking or cycling to work has therefore been promoted as public health's easiest win. The evidence behind that promotion, though, has been contradictory, with individual cohorts pointing in different directions. This review set out to pool the mortality data and ask a sharper question: does active commuting actually track lower death rates, and does the amount of it matter?

The authors searched PubMed, the Cochrane Library, Embase and Science Direct for studies that reported mortality data alongside walking or cycling to or from work. Seventeen studies representing 829,098 workers met the criteria. Results were pooled and then split by type of mortality, by type of commuting and by level of commuting. Each split was run twice, once using the fully adjusted risk estimates from the original papers and once using crude or less adjusted estimates, so readers could see how much the adjustment mattered.

Using the fully adjusted estimates, active commuting was associated with 9% lower all-cause mortality and 15% lower cardiovascular mortality. Split by mode, walking was linked to 13% lower all-cause mortality, while cycling was linked to 21% lower all-cause and 33% lower cardiovascular mortality. Amount mattered: only a high level of active commuting was associated with lower all-cause mortality, intermediate and high levels with lower cardiovascular mortality, and a low level with no reduction in any type of mortality. Cancer mortality did not fall with walking or cycling in the fully adjusted models, appearing only in the crude or less adjusted analyses.

This pulls a contradictory literature into a single dose-response picture, with the strongest signals for cycling and for higher amounts of walking. It cannot settle causation, because people who cycle to work were never randomly assigned to do so and may be healthier, wealthier or living in more walkable places to begin with. The cancer finding is a useful warning about interpretation: it appeared only when adjustment was looser. Open questions include how much of cycling's advantage comes from its intensity rather than the person, and whether these estimates hold in cities with very different infrastructure.

The finding is a reason to view an active commute as genuine exercise rather than mere logistics, particularly if it is done by bike or as a longer walk. It is also a reason to be honest about volume, since the smallest amounts of active commuting were not linked to any mortality benefit here. Nothing in this pooling tells you that switching your commute will change your own risk, only that the people who commute actively tend to die less often over follow-up. If you already walk or ride, that is a point in your column rather than a target to chase.